Clinical Course and Risk Factors for In-Hospital Mortality of 205 Patients with SARS-CoV-2 Pneumonia in Como, Lombardy Region, Italy
Article
[키워드] age
Analysis
analyzed
Anticoagulant
anticoagulation
Antiviral
antiviral drugs
antiviral therapy
C-reactive protein
Characteristics
clinical
clinical risk factor
Comorbidities
Coronavirus disease 2019
Course
COVID-19
COVID19
CRP
disease
drug
Effectiveness
elevated
Factor
greater
Hydroxychloroquine
In-hospital death
in-hospital mortality
infected with SARS-CoV-2
inhibitors
interleukin-6
Intervention
Italy
Laboratory
laboratory-confirmed
lactate dehydrogenase
LDH
less
lombardy
management
Mortality
Multivariable regression
multivariate logistic regression
Older
outbreak
P/F ratio
pathway
Patient
patients treated
Pneumonia
prognostic
reduction in mortality
Region
Result
risk factor
Risk factors
SARS-CoV 2
SARS-CoV-2
SARS-CoV-2 pneumonia
significant effect
single-center
Steroids
supportive care
tested
therapy
Tocilizumab
tocilizumab therapy
treat
Treatment
treatment strategy
[DOI] 10.3390/vaccines9060640 PMC 바로가기 [Article Type] Article
[DOI] 10.3390/vaccines9060640 PMC 바로가기 [Article Type] Article